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Orofacial  pain  is  related  to tissues  of  the  head,  face,  neck  and  all the intraoral  structures;  it  is rather  debil-
itating  to the  patient  and also  difﬁcult  to treat.  There  are relatively  few  studies  dedicated  to  the  use of
natural  products  to alleviate  orofacial  pain  in  preclinical  experiment  models  (performed  in  experimen-
tal  animals  which  provide  support  for clinical  trials).  Main  objectives  of  the  present  systematic  review
summarize  the  studies  on  natural  products  assessed  in  animal  models  for orofacial  pain  seeking  to  give
evidence  to future  development  of new  pharmaceutical  products  to manage  the  orofacial  pain.  Our  review
includes  a  thorough  search  of  literature  using  the  terms  of  orofacial  pain,  facial  pain,  medicinal  plants
and  natural  products.  This  search  was  performed  using  to  retrieve  English  language  articles  in Medline-
PubMed,  Scopus  and  Web  of  Science.  A  total  of eighteen  studies  were  included  in  our survey  for  the inclu-
sion criteria.  Firstly,  this  review  identiﬁed  210  citations  from  electronic  search,  after  removal  of  duplicates
and  screening  for relevant  titles  and  abstracts,  a total  of eighteen  articles  were  selected  to the  inclusion
criteria  established.  Our  ﬁndings  suggest  that natural  products  can  be a  promising  or a trump  tool  for  the
development  of  new  drugs  to treat  orofacial  pain  conditions,  but  the  researchers  that  deal  with  experi-
mental preclinical  trials  of  new drugs  (including  natural  products  or synthetic  drugs)  for  orofacial  pain
conditions  urgently  need  to  show  translational  evidence  (with  clinical  approach)  of  these  compounds.
© 2016  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  This  is an  open
he CCaccess  article  under  t
ntroduction
Orofacial pain is related to tissues of the head, face, neck and
ll the intraoral structures determined by the American Academy
f Orofacial Pain (AAOP). This pain condition represents a highly
revalent spectrum of disorders with pain intensity involving
natomical, biochemical and molecular aspects which are associ-
ted with psychosocial components (Hargreaves, 2011; Fan et al.,
012). The orofacial region is one of the most densely innervated
reas of the body, and the trigeminal nerve plays an important
ole in this process. An orofacial pain encompasses a wide range
f conditions including temporomandibular joint disorders, peri-
dontal pain, trigeminal neuralgia, atypical facial pain, burning
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mouth syndrome, dental surgical pain, head and neck cancer pain,
pain due to oral infections, and other neuropathic and inﬂamma-
tory pain (Gilbert et al., 2001). It is also the site of frequent chronic
post-herpetical neuralgia, migraine and referred pains (Pelissier
et al., 2002; Raboisson and Dallel, 2004). Therefore, orofacial pain is
often rather debilitating to the patient and many difﬁculties in the
management of acute and chronic orofacial pain conditions stem
from a lack of recognition and understanding of pain mechanisms
(Miranda et al., 2009; Krzyzanowska and Avendan˜o, 2012).
Up to the present date, several animal models have been used
to study orofacial pain. These include infraorbital nerve ligation or
axotomy, injection of inﬂammatory agents into the vibrissal pads,
temporomandibular joint or masseter muscle, as well as intradental
or dural application of irritants (Ren and Dubner, 1999). Clavelou
et al. (1989) reported that the adaptation of the formalin model
of pain for the orofacial region provides an important contribu-
tion to the mechanisms of trigeminal pain and analgesic response
ora Ltda. This is an open access article under the CC BY-NC-ND license (http://
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Search pubmed (88), Scopus (68), Web of science (54) databases
210 original articles 
53 articles dee med
potentially relevant
157 citations excluded:
not relevant by  title
review
33 citations  excluded:
not relevant by abstract
review 20 articles deemed
relevant by title and
abstract or needed full
text to  make
determinati on
18 articles included 
4 citations excluded:
not relevant by  full text
review 
Inclusion of 2 articles
fro m reference  listP.S. Siqueira-Lima et al. / Revista Brasi
Mittal et al., 2009). Other orofacial pain animal models have
een more recently proposed and have contributed with clinical
tudies, such as the assessment of neuropathic and inﬂammatory
ain (Krzyzanowska and Avendan˜o, 2012). Despite the impor-
ance of these animal models, according to Khan and Hargreaves
2010), they pose some limitations that should always be taken into
ccount in the choice of models for the testing of new drugs. Thus,
hese animal models have great an importance to the study, such
s a better understanding, development of therapeutic proposals
nd advances in the treatment of orofacial pain.
The management of pain is still a major challenge to both
he medical practitioners and the patients (Krzyzanowska and
vendan˜o, 2012). Opioids, antidepressants, anticonvulsants and
on-steroidal anti-inﬂammatory drugs (NSAID) remain as the main
gents used to relieve acute and chronic pain, including orofacial
ain (Pace et al., 2006), but the wide range of side-effects aligned
ith low adherence has been a stimulus in the constant search
or new drugs to treat orofacial pain (Quintans-Júnior et al., 2010).
n actual approach is to develop a new biological compound that
nhibits pain from natural products (NP), such as medicinal plants
r their secondary metabolites, which could enhance efﬁcacy, pro-
uce minimal side effects and operate in unusual ways compared
o the synthetic drugs (Holanda-Pinto et al., 2008; Venâncio et al.,
011; Oliveira et al., 2012).
The present systematic review was designed to summarize
he current studies on NP tested in animal models for attenuat-
ng the orofacial pain. Our main focus aimed to make the reader
ware, through a systematic way, of which the main aspects of NP
esearched to orofacial pain are, in experimental protocols.
ethods
earch strategy
Three internet sources were used to search for appropriate
apers that met  the study purpose. These included the National
ibrary of Medicine, Washington, D.C. (Medline-PubMed), Scopus
nd, Web  of Science using different combinations of the follow-
ng keywords: Orofacial pain, Facial pain, Medicinal plants, natural
roducts. The databases were searched for studies conducted in the
eriod up to and including April 30, 2015. The structured search
trategy was designed to include all published papers that evalu-
ted the use of natural products in orofacial pain. Citations were
imited to animal studies. Additional papers were included in our
tudy after the analyses of all references from the selected articles.
e did not contact investigators and did not attempt to identify
npublished data.
tudy selection
All electronic search titles, selected abstracts, and full-text arti-
les were independently reviewed by a minimum of two reviewers
JSSQ and PSSL). Disagreements in study inclusion/exclusion were
esolved with a consensus meeting with more reviewers. The
ollowing inclusion criteria were applied: orofacial pain studies,
nimal models and the use of NP for reducing nociception. Stud-
es were excluded according to the following exclusion criteria:
tudies in humans, review articles, meta-analyses, abstracts and
onference proceedings.
ata extractionData were extracted by one reviewer using standardized forms
nd were checked for completeness and accuracy by a second
eviewer. Information collected included data regarding the studyFig. 1. Flow diagram for literature searching and screening.
substance (natural products), animal, dose (route), model, recep-
tors/mediators, antagonists and results.
Methodological quality assessment of studies
The risk of bias and quality of the study design were assessed
using a 12-point checklist. The use of these questions has
enabled the assessment of important aspects that contribute to
the quality of the study, such as randomization of the treat-
ment allocation, blinded drug administration, blinded outcome
assessment and outcome measurements. Studies that reported
randomization of animals, blinding and outcome measurements
were considered of higher methodological quality (Zeng et al.,
2015).
Results and discussion
The preliminary review of the present study identiﬁed 210 cita-
tions from electronic search, with 88 from Pubmed, 68 from Scopus,
54 Web  of Science. After removal of duplicates and screening for rel-
evant titles and abstracts, a total of eighteen articles were selected
to the inclusion and exclusion criteria established (Fig. 1).
Curiously, from eighteen ﬁnal studies selected, most of that
research, particularly NP, was  conducted in Brazil (88%) (Table 1)
and 12% in India and USA. Details of the included studies are
described in Table 1. That could be because we limit our inclu-
sion criteria to orofacial pain animal models. However, if this
survey sought clinical studies and/or ethnopharmacological search,
it probably showed a wider range of countries (Tapsoba and
Deschamps, 2006; Taheri et al., 2011). Another factor may  have
contributed to this ﬁnding because Brazil has the extensive ethical,
cultural and greatest biodiversity in the world, which has histor-
ically been a source of exploration and study (Maciel et al., 2002;
Oliveira et al., 2012). The result shows the scientiﬁc growth of Brazil
in the area of NP corroborating with the potential of biological
diversity (Peixoto and Morim, 2003) that has about 19% of earth’s
total diversity (Giulietti et al., 2005). Also, it is estimated that 49,000
plant species have already been described (Shepherd, 2002).
Traditionally, people believe that the NP from plants used in
folklore medicine for therapeutic purposes have contributed over
the years to obtain various drugs widely used in a clinical purpose
(Cechinel-Filho and Yunes, 1998). Actually, about half of the drugs
used are derived from natural sources (Kumari et al., 2012). The
medical prescriptions of the United States prescribe 25% of natural
substances as active ingredients obtained from plants of temperate
and tropical regions; from as estimate of $900 million, about half of
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Table  1
Characteristics of studies inserted in the review.
Authors, year,
country
Substance/chemical
group/(natural
product)
Animals
(strain/sex)
Dose (route) Method of induction of
orofacial pain
Parameters assessed R B
Behavior Biochemical/
molecular
Gilbert et al., 2001,
USA
Epibatidine Rats (SD/M)  1–5 g/kg 50 l subcutaneous
injection of formalin (5%)
into one vibrissal pad
Grooming,
rubbing and/or
scratching face
– N Y
Mittal et al., 2009,
India
Curcumin
(Curcuma longa)
Rats (W/M)  1–600 mg/kg
(i.p.)
50 l subcutaneous
injection of formalin (5%)
into one vibrissal pad
Grooming,
and/or
scratching face
– N N
Holanda-Pinto
et al., 2008, Brazil
,-amyrin
(Protium
heptaphyllum)
Rats (W/M) 10–100 mg/kg
(i.p.)
20 l subcutaneous
injection of formalin
(1.5%), capsaicin (1.5 g)
into one vibrissal pad
Face-rubbing – N N
Siqueira et al.,
2010, Brazil
Atranorin
(AT)/Liquen
(Cladina kalbii
Ahti)
Mice (S/M)  100–400 mg/kg
(i.p.)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g)
into the right upper lip
(perinasal area)
Face-rubbing – N N
Quintans-Júnior
et al., 2010, Brazil
Citronellal
(Cymbopogon
genus)
Mice (S/M)  50–200 mg/kg
(i.p.)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g),
40 l glutamate (25 M)
into the right upper lip
(perinasal area)
Face-rubbing Single sucrose gap
electrophysiologic
assays
Y N
Bonjardim et al.,
2011, Brazil
Ethanol,
chloroform,
methanol extract
fractions (S.
cordifolia)
Mice (S/M)  100–400 mg/kg
(p.o.)
20 l subcutaneous
injection of formalin
(2%), 40 l glutamate
(25 M)  into the right
upper lip (perinasal area)
Face-rubbing – N N
Venancio et al.,
2011, Brazil
(Ocimum
Basilicum) and
(−)-linalool
Mice (S/M)  50–200 mg/kg
(i.p.)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g),
40 l glutamate (25 M)
into the right upper lip
(perinasal area)
Face-rubbing Field potential
recordings.
electrophysiologic
assays
N  N
Santana et al.,
2011, Brazil
p-Cymene Mice (S/M)  25–100 mg/kg
(i.p.)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g),
40 l glutamate (25 M)
into the right upper lip
(perinasal area)
Face-rubbing – N N
Brito et al., 2013,
Brazil
Citronellol
(Cymbopogon
citrates,  C.
winterianus)
Mice (S/M)  25–100 mg/kg
(i.p.)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g),
40 l glutamate (25 M)
into the right upper lip
(perinasal area)
Face-rubbing Immunoﬂuorescence Y N
Guimarães et al.,
2012, Brazil
Carvacrol Mice (S/M)  25–100 mg/kg
(i.p.)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g),
40 l glutamate (25 M)
into the right upper lip
(perinasal area)
Face-rubbing – Y N
Paixão et al., 2013,
Brazil
Aqueous extract
(Hyptis pectinata)
Mice (S/M)  100–400 mg/kg
(p.o.)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g),
40 l glutamate (25 M)
into the right upper lip
(perinasal area)
Face-rubbing TBARS
DPPH
Y N
Lima et al., 2013b,
Brazil
Hydroethanol
extract (Hyptis
fruticosa)
Mice (S/M)  50–200 mg/kg
(p.o.)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g),
40 l glutamate (25 M)
into the right upper lip
(perinasal area)
Face-rubbing TBARS Y N
Nomura et al.,
2013, Brazil
Ethanolic extract
(Acmella oleracea)
Mice (S/M)  10–100 mg/kg
(i.p)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g),
cinnamaldehyde
(13.2 g) into the right
upper lip (perinasal area)
Face-rubbing – N N
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Table  1
(Continued)
Authors, year,
country
Substance/chemical
group/(natural
product)
Animals
(strain/sex)
Dose (route) Method of induction of
orofacial pain
Parameters assessed R B
Behavior Biochemical/
molecular
Quintans et al.,
2014a, Brazil
Ethanolic extract
(Syzygium cumini)
Mice (S/M)  100–400 mg/kg
(p.o)
20 l subcutaneous
injection of formalin
(2%), 40 l glutamate
(25 M)  into the right
upper lip (perinasal area)
Face-rubbing – Y Y
Siqueira-Lima
et al., 2014, Brazil
-Cyclodextrin
complex
containing
essential oil
(Lippia grata)
Mice (S/M) 6–24 mg/kg
(p.o)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g),
40 l glutamate (25 M)
into the right upper lip
(perinasal area)
Face-rubbing Immunoﬂuorescence Y Y
Quintans et al.,
2014b, Brazil
Hexanic extract
(Combretum
duarteanum) and
friedelin
Mice (S/M)  100–400 mg/kg
(p.o)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g),
40 l glutamate (25 M)
into the right upper lip
(perinasal area)
Face-rubbing – Y Y
Damascena et al.,
2014, Brazil
Aqueous extract
(Anadenanthera
colubrina)
Mice (S/M)  100–400 mg/kg
(p.o)
20 l subcutaneous
injection of formalin
(2%), capsaicin (2.5 g),
40 l glutamate (25 M)
into the right upper lip
(perinasal area)
Face-rubbing DPPH, MDA, TBARS,
AAPH, FeSO4
Y N
Nowacki et al.,
2015, Brazil
Hydroalcoholic
extract
(Hypericum
perforatum,
Valeriana
ofﬁcinalis, Piper
methysticum)
Mice (S/M)  NR 20 l subcutaneous
injection of formalin
(2%) into the right upper
lip (perinasal area)
Face-rubbing Hematological and
hepatic markers
N N
Animals: SD, Sprague–Dawley; W,  Wistar; S, Swiss.
Parameters assessed: DPPH, 2,2-diphenyl-1-picrylhydrazyl radical; MDA, malonaldehyde; TBARS, thiobarbituric acid-reactive substances; AAPH, 2,2′-azobis(2-
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Regarding the NP used for the management of orofacial pain
abulated in the present study, (Table 1) shows isolated substance
47.25%), extracts (47.25%) and -cyclodextrin (-CD) complexes
ontaining essential oil (5.5%). That interprets most reviews of
solated compounds as reﬂecting the importance of the pharma-
eutical industry, since the drugs are, almost entirely, a single active
ngredient which is responsible for its pharmacological effect.
everthless, the plant extracts consist of multicomponent active
ixtures, partially active and inactive substances, which often
ork in different pharmacological targets (Ferreira and Pinto, 2010;
lrich-Merzenich et al., 2010).
Moreover, our ﬁndings demonstrated that it is necessary to
ncrease the number of studies with NP to orofacial pain mod-
ls because 100% of the included studies in the present review
se mainly chemical stimuli to induce pain (formalin, glutamate,
apsaicin or cinnamaldehyde) into the vibrissal pad. These charac-
eristics of the studies found become obvious limitations because
rofacial pain is derived from many unique target tissues, such
s the meninges, cornea, tooth pulp, oral/nasal mucosa and tem-
oromandibular joint (Hargreaves, 2011). Further, there are other
rofacial pain animal models also established in the literature,
uch as orofacial neurophatic pain or chronic pain model in
emporomandibular joint, which have not been explored in arti-
les inserted in this systematic review. According to Raboisson
nd Dallel (2004), the mechanisms underlying orofacial pain are
till poorly understood, partly due to the relative scarcity ofization; B, reporting of blinding; Y, yes; N, no.
investigation devoted to the face and the mouth, when compared
with pain in body. In particular, there are relatively few behavioral
models in laboratory animals dedicated to the study pain in the
trigeminal region.
Regarding the analysis of quality of the studies inserted, we
found that 50% of studies (9) mentioned randomization in the
allocation of animals for testing. However, they did not describe
how they performed randomization of animals. Moreover, only
four studies (22%) were performed by double-blind manner, as it
can be seen in Fig. 2. That limits the interpretation of the results
obtained in our review, what shows a low quality in the studies
found.
To better describe and understand the results, we summa-
rized them as isolated compounds, plant species, essential oils and
extracts, which are described below.
Isolated substance
Epibatidine (1)
Epibatidine is a strong toxic alkaloid that is secreted from the
Epipedobates anthonyi (Noble) (synonym Epipedobates tricolor) frog,
which lives in Central and Southern Ecuador (Fitch et al., 2010). Epi-
batidine isolated from these frogs showed an effective analgesic and
anti-inﬂammatory effects and was  further assessed in the orofacial
pain induced by the formalin animal model (Gilbert et al., 2001).
According to authors, the acute treatment with epibatidine can pro-
duce a neuronal nicotinic receptor-mediated antihyperalgesia in
both dose- and time-dependent manner.
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Is the hypothesis/aim/objective of the study clearly described?
Are the main outcomes to be measured clearly described in the Introduction/
Methods section?
Are the main findings of the study clearly described?
Were sample size calculations reported?
Was the allocation adequately concealed?
Were the caregivers and/or investigators blinded from knowledge which
intervention each animal received during the experiment?
Were animals selected at random for outcome assessment?
Was the outcome assessor blinded?
Was the agent used to induce pain reported?
Was the dose to the algic agent reported?
Yes
14
9
18
18
18
No Unclear
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hat  did not and white bars indicate the proportion of studies with unclear answers
 
urcumin (2)
The major bioactive constituent of the oleoresin of turmeric
Curcuma longa L., Zingiberaceae) demonstrated a signiﬁcant
eduction in grooming behavior induced with formalin in a
ose-dependent manner in both phases. Curcumin has proven
nti-inﬂammatory effect demonstrating its beneﬁcial role for this
ain condition (Mittal et al., 2009). Kim et al. (2003) explains
he anti-inﬂammatory activity of curcumin due to its inhibitory
ction on Janus kinase (JAK) – STAT signaling pathway in brain
icroglial cells, which contributes to the attenuation of inﬂam-
atory response. Anti-inﬂammatory activity of curcumin may  also
e related to its ability to directly suppress nuclear factor-kappa B
NF-B), leading to the inhibition of cellular COX-2 gene expres-
ion. Curcumin also causes an indirect suppression of the NF-B an
ctivity by inhibiting the degradation of the inhibitory unit I-B,
hich hampers subsequent nuclear translocation of the function-
lly active subunit of NF-B (Surh et al., 2001). Also, it has been
hown to overturn the synthesis of prostaglandin E2 (PGE2), which
s known to be involved in mediating acute inﬂammation (Goel
t al., 2001). There are also evidences of the inhibition of pro-
nﬂammatory cytokine production (TNF-,  IL-1, IL-8) by curcumin
Xu et al., 1997–1998; Banerjee et al., 2003; Jacob et al., 2007).
nother study explains that the oxygen radical scavenging activity
f curcumin has also been implicated to anti-inﬂammatory effects
Kunchandy and Rao, 1990). In addition to the anti-inﬂammatory
roﬁle, Sharma et al. (2006, 2007) demonstrated the efﬁcacy of
urcumin in the attenuation of diabetic neuropathic pain. Accord-
ng to Mittal et al. (2009), one needs to explain the mechanism
f curcumin in the ﬁrst phase of formalin, which occurs as a
irect activation of A-delta and C-nociceptors as well as trigem-
nal and spinal nociceptive neurons, whereas anti-inﬂammatory
ction over the various mechanisms mentioned above might be
esponsible for reducing the grooming behavior during the tonic
hase. Banafshe et al. (2014) explains that this antinociceptive
ffect may  be due to the activation of the opioid system. Based of articles that met  each criterion; light gray bars indicate the proportion of studies
on these reports, the compound curcumin represents a natural
source for the treatment of orofacial and attenuating other pain-
and inﬂammation-related disorders, which all need future clinical
investigations.
˛,ˇ-Amyrin
The effects of the pentacyclic triterpene isolated from Pro-
tium heptaphyllum (Aubl.) Marchand, Burseraceae, was investigated
on rat model of orofacial pain induced by formalin or capsaicin.
The results show that pretreatment with ,-amyrin produces
pronounced anti-nociception as evidenced by the decreased face
rubbing behavior in capsaicin test and in the second phase of the
formalin test (Holanda-Pinto et al., 2008). The inhibitory effect
observed with ,-amyrin on capsaicin and in the second phase
of formalin-induced facial grooming may  be a result of its possible
inhibition on the Substance P release or due to a direct blocking
action on its neurokinin-1 receptor (NK-1) (Holanda-Pinto et al.,
2008). In this context, a previous study provided evidence for
the tonic activation of NK-1 receptors during the second phase of
the formalin test in the rat, and systemically administered, NK-1
receptor antagonist SR14033 blocks only the second phase of the
orofacial formalin test (Henry et al., 1999; Luccarini et al., 2003).
A recent study demonstrated the decreased NK-1 immunoreac-
tivity in animals treated with ,-amyrin in the rat model of
visceral nociception induced by cyclophosphamide (Lima-Júnior
et al., 2007). Silva et al. (2011) demonstrated that ,-amyrin
exhibits long-lasting antinociceptive and anti-inﬂammatory prop-
erties in models of CFA-induced inﬂammation and hyperalgesia via
the activation of cannabinoid receptors and by inhibiting the pro-
duction of cytokines, expression of nuclear factor B (NF-B) and
cyclic adenosine monophosphate response element binding (CREB)
and COX-2. Hence, from all these studies the ,-amyrin involves
in most of the central and peripheral mechanisms and exhibits
antinociceptive and anti-inﬂammatory effects, offering themselves
as a better candidature for clinical assessment of orofacial pain
disorders.
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tranorin (3)
Siqueira et al. (2010) evaluated the antinociceptive effect of
tranorin on formalin- and capsaicin-induced orofacial pain in
ice. Their results showed that acute administration of atranorin
400 mg/kg, i.p.)  in formalin-induced orofacial pain results in a pro-
ounced anti-nociception as evidenced by decreased face-rubbing
ociceptive behavior in the ﬁrst and second phases of the formalin
est. All doses of atranorin signiﬁcantly inhibited the face-rubbing
ehavior at the second phase of the formalin test just as in the
apsaicin test. Therefore, the study suggested a possible antinoci-
eptive effect of this important lichen metabolite extracted from
ladina kalbii Ahti, in unspeciﬁc tests (Melo et al., 2008). This effect
ay  have resulted from the inhibition of the Substance P release or
ue to a direct blocking action on its neurokinin-1 receptor (NK-1)
Holanda-Pinto et al., 2008). Melo et al. (2008) suggested a pos-
ible antinociceptive effect of atranorin to act peripherally on the
nﬂammatory mediators, especially on prostaglandins. Bugni et al.
2009) showed that a part of the antinociceptive effect obtained
ith atranorin may  be due to the COX inhibition. Additionally, it
as demonstrated that atranorin effectively inhibited the biosyn-
hesis of leukotriene B4 in bovine polymorphonuclear leukocytes,
hich could also lead to an anti-inﬂammatory effect (Kumar and
uller, 1999). The precise mechanisms through which atranorin
xerts its action are currently under investigation, but they could
ossibly be related to the arachidonic acid cascade and/or mod-
lation of pro-inﬂammatory molecule production (Siqueira et al.,
010).
itronella
Reports from Quintans-Júnior et al., 2010, revealed the effects
f citronellal, a monoterpene from the oils of Corymbia citriodora
Hook.) K.D. Hill & L.A.S. Johnson, Myrtaceae, Cymbopogon nardus
L.) Rendle, C. citratus (DC.) Stapf and C. winterianus Jowitt ex Bor,
oaceae, in the possible anti-nociceptive activity by using orofacial
ociceptive tests (formalin-, capsaicin-, and glutamate-induced
rofacial nociception) and investigated whether such effects might
ause a change to neural excitability. Their results showed that
n acute administration of citronellal caused pronounced anti-
ociception as evidenced by decreased face-rubbing behavior in
he ﬁrst and second phases of the formalin test, suggesting that
itronellal has a central analgesic effect. To conﬁrm such an effect,
he blocking effect of naloxone, a speciﬁc antagonist of  morphi-
omimetic receptors, was tested on both phases of the formalin
est (Belvisi et al., 1998). Its antagonist effects suggested the par-
icipation of the opioid system in the modulation of nociception
nduced by citronellal. Citronellal also inhibited nociceptive behav-
or induced by the capsaicin injection into the right upper lip.
he inhibitory effect observed with citronellal on capsaicin- and
ormalin-induced face-rubbing behavior seems similarly act to ,-
myrin, which can involve the inhibition of the Substance P release
r the action on receptor neurokinin-1 (NK-1) (Holanda-Pinto et al.,
008). The results also showed that the intraperitoneal adminis-
ration of the citronellal produced a signiﬁcant inhibition of the
ociceptive response induced by the right upper injection of glu-
amate into mice. That nociceptive response induced by glutamate
eems to involve peripheral, spinal and supraspinal sites and its
ction is mediated by NMDA and non-NMDA receptors (Beirithe Farmacognosia 27 (2017) 124–134 129
et al., 2002). Thus, the suppression of glutamate-induced nocicep-
tion by citronellal treatment can be associated with the interaction
of citronellal with the glutamatergic system (Ferreira et al., 1999).
The present study used the single sucrose gap method to show
that citronellal could reduce the excitability of isolated nerves
through a diminution of amplitude of compound action potential
(CAP). It is possible that the antinociceptive effects of citronel-
lal in the experimental models of nociception could be involved
in voltage-gated Na+ channel blocking, and may also have CNS
effects (Quintans-Júnior et al., 2010). Quintans-Júnior et al. (2010,
2011) also proposed that the orofacial antinociceptive effect of
citronellal could be related to the antioxidant proﬁle since these
monoterpenes exhibited a signiﬁcant antioxidant activity as seen
in TRAP/TAR assays, and scavenge NO and superoxide molecules
which are widely accepted methods to reliably establish the abil-
ity of isolated molecules to act as general antioxidants in vitro
(Salvemini et al., 2006; Guimarães et al., 2010). Thus, citronellal
when clinically tested could form a promising source of drug for
treating orofacial pain disorders.
p-Cymene
Santana et al. (2011) investigated the antinociceptive poten-
tial of p-cymene, a monoterpene biological precursor of carvacrol
and one of the main constituents of the essential oil obtained
from species of Protium. p-Cymene signiﬁcantly reduced the noci-
ceptive behavior in the ﬁrst and second phases of orofacial
nociception in all models induced by formalin, capsaicin and glu-
tamate, suggesting an action in both neurogenic and inﬂammatory
pain. Recently, Santana et al. (2015) demonstrate that p-cymene
anti-hyperalgesic shows an effect against carrageenan, TNF-,
dopamine and PGE2 tests. The anti-hyperalgesic effect seems to
be related to the capacity of p-cymene to decrease total leukocyte
migration, TNF- levels, act in opioid receptors and increased num-
ber of c-Fos-immunoreactive neurons in periaqueductal gray (PAG)
area. Quintans et al. (2013) suggested that p-cymene could have its
analgesic and anti-inﬂammatory effect enhanced by complexation
with cyclodextrins probably by increasing the bioavailability of the
terpenoid.
Citronellol
Brito et al. (2013) evaluated the antinociceptive effects of cit-
ronellol on orofacial nociception in mice and also investigated the
central pathway system involved in the effect. This monoterpenoid
alcohol is present in essential oils of various aromatic plant species
such as Cymbopogon citratus and C. winterianus; its administration
produced a reduction in the face rubbing behavior induced by for-
malin in ﬁrst and second phases, which may  be associated with
the blockade of the voltage-dependent Na+ channels (Butler, 2008;
Gonc¸ alves et al., 2008; De Souza et al., 2006). All test doses of cit-
ronellol signiﬁcantly reduced the face rubbing behavior induced
by the administration of capsaicin. This inhibition observed in the
effect of the formalin and capsaicin tests has been suggested to
result from an inhibition of substance P or by a blocking action on
neurokinin-1 receptor (NK-1), because studies demonstrated the
evidence for the activation of NK-1 receptors, through the NK-1
antagonist administration blocking the second-phase formalin test
(Luccarini et al., 2003; Holanda-Pinto et al., 2008). The results of the
orofacial nociception induced by the glutamate show that citronel-
lol, in all doses, signiﬁcantly decreased the face rubbing behavior
compared with the control group, thus suggesting its interaction
with the glutamatergic system. Brito et al. (2013) showed that
citronellol signiﬁcantly increased the average number of neurons
in the olfactory bulb, piriform cortex, retrosplenial cortex (RSP)
and in the PAG of the animal brains when compared with the
control (vehicle). Thus, it can be suggested that citronellol pro-
duced orofacial antinociceptive effect probably by the inhibition
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f peripheral mediators, as well as the activation, direct or indirect,
f CNS regions.
arvacrol
This monoterpene is predominant in many essential oils from
he family Lamiaceae, including the Origanum and Satureja species.
uimarães et al. (2012) reported that acute treatment with car-
acrol plays a protective role in reducing behavioral pain when
creened for formalin-, capsaicin-, and glutamate-induced orof-
cial nociception in mice. According to the authors, carvacrol seems
o produce anti-nociception in the orofacial formalin-, capsaicin-
nd glutamate-tests due to its effects in the reduction of the neu-
onal excitability and voltage-gated Na+ channel (NaV) inhibition
n peripheral neurons (Joca et al., 2015) or to produce analgesic and
nti-inﬂammation effects by the modulation of cytokines, such as
L-10, IL-1 or TNF- (Guimarães et al., 2014, 2015). Additionally,
he carvacrol effects on the CNS were assessed through immu-
oﬂuorescence for Fos protein. Furthermore, molecular docking
tudies were performed to evaluate intermolecular interactions of
he carvacrol and muscimol, as ligands of IL-10 and GABAA recep-
ors, which showed the neuromodulatory properties of carvacrol
n the brain areas that comprise the descending-pain pathway con-
rol, such as PAG, nucleus raphe magnus (NRM) and locus ceruleus
LC). In addition, carvacrol complexed in -cyclodextrin (-CD) had
rolonged analgesic effect and acted on descending-pain inhibitory
athway without showing tolerance and in a smaller dose than
he carvacrol isolated as they were rendered highly bioavailable
Barreto et al., 2014; Guimarães et al., 2014, 2015).
Additionally, Lima et al. (2013a) evaluated the contribution
f the cytokine modulation to the anti-inﬂammatory effects of
arvacrol in complete Freund’s adjuvant (CFA) model. Hence,
he administration of this substance produced anti-inﬂammatory
ffects and attenuated the paw edema and reduced the IL-1 and
GE2, but not TNF-, local levels. That effect suggested that car-
acrol caused anti-inﬂammatory effects by reducing the production
f inﬂammatory mediators, such as IL-1 and prostanoids, possi-
ly through the induction of the IL-10 release. Banji et al. (2014)
sed the same model, CFA, as Lima et al. (2013a), but Banji et al.
sed a combination of carvacrol with methotrexate observing that
his association enriches the therapeutic beneﬁt enhancing its anti-
rthritic action and minimizing its toxicity.
lant species, essential oils and extracts
ida cordifolia L., Malvaceae
This plant is a native species of Northeastern Brazil, popularly
nown as “malva-branca”. Pharmacological activity of the extracts
nd fractions from S. cordifolia in two animal models of orof-
cial nociception has been previously reported (Bonjardim et al.,
011). Administration of ethanol extract (EE), chloroform (CF) and
ethanol (MF) fractions from S. cordifolia produced a reduction in
he face rubbing behavior induced by formalin. All doses tested sig-
iﬁcantly increased anti-nociception both in the ﬁrst and second
hase compared with the control (vehicle). Morphine (MOR) was
ble to reduce nociceptive behavior in both phases. The effects of EE,
F, MF  and MOR  were antagonized by naloxone. The treatment with
F and MF  signiﬁcantly reduced the nociceptive behavior induced
y glutamate in relation to the control group. Thus, it is suggested
hat the constituents of this fraction could interfere in the gluta-
atergic system, through the activation of NMDA receptors, which
ould limit the production of NO and other inﬂammatory media-ors (Ribas et al., 2008). Henceforth, the antinociceptive effect of the
thanol extract from S. cordifolia and its chloroform and methanol
ractions is probably due to the presence of alkaloids and ﬂavones.
dditionally, it seems at least in part that this antinociceptive actione Farmacognosia 27 (2017) 124–134
of EE, CF and MF  involves the opioid and the glutamatergic systems
(Bonjardim et al., 2011).
Hyptis pectinata (L.) Poit., Lamiaceae
Paixão et al. (2013, 2015) investigated the effect of the aque-
ous extract from H. pectinata (AEPH) on the orofacial nociceptive
models and its antioxidant potential. The results of the present
study showed that AEPH is active against neurogenic and inﬂam-
matory pain since it inhibits the mice face-rubbing nociceptive
behavior in both phases. In addition, when the mechanism of
AEPH action was  investigated using naloxone, its effect was  not
reversed, suggesting that its analgesic activity does not involve opi-
oid receptors. Bispo et al. (2001) found that naloxone (5 mg/kg,
i.p.) markedly reversed the antinociceptive effect of the aqueous
extract (200 mg/kg) and of morphine (10 mg/kg) in the hot-plate
test. In order to better assess this aspect, Lisboa et al. (2006) eval-
uated the non-selective opioid antagonist naloxone (5 mg/kg, i.p.),
which was co-administrated with chloroform (200 mg/kg), ethyl
acetate (100 mg/kg) and hexane extracts (100 mg/kg), since nalox-
one reversed the antinociceptive effect. This mechanism is similar
to that found in the volatile oil of H. pectinata, in which the admin-
istration (i.p.) of the opioid agonist naxolone (5 mg/kg body wt)
completely reversed the antinociceptive effect of the volatile oils
of all genotypes on the hot-plate test, suggesting that opioid recep-
tors are involved in its antinociceptive action (Arrigoni-Blank et al.,
2008; Raymundo et al., 2011). Other mechanisms of volatile oil of
H. pectinata were also investigated. l-NAME signiﬁcantly reversed
the effects of the EO in the acetic acid-induced contortions and
hot-plate models and atropine completely reversed in all mod-
els. Besides, the EO inhibited the inﬂammatory process induced
by subcutaneous carrageenan injection by reducing cell migration,
exudate volume, protein concentration and inﬂammatory media-
tors (nitric oxide, PGE2, IL-6, and TNF-) (Raymundo et al., 2011).
To further investigate the mechanism through which AEPH
acts against orofacial pain, capsaicin was used, and there was a
reduction in the capsaicin nociceptive effect in a dose-dependent
manner, which indicates AEPH is acting as an antagonist of vanil-
loid receptors, possibly by inhibiting the initial release of substance
P or bounding into its neurokinin 1 receptor. AEPH exhibited signif-
icant antinociceptive activity when the glutamate model was  used.
Therefore, it can be suggested that it interferes with the glutamater-
gic system. In vitro studies of this study showed that AEPH has an
important neurogenic and inﬂammatory orofacial antinociceptive
effect, without interference in the motor performance (Paixão et al.,
2013).
Recently, the literature has shown that the analgesic and anti-
inﬂammatory effects of H. pectinata can be improved with the
incorporation into complexing systems (as cyclodextrins) or vec-
torization of drugs, which can bring beneﬁts to physicochemical
or pharmacological aspects of pharmaceutical preparations con-
taining extracts or essential oils of medicinal plants (Oliveira et al.,
2015; Brito et al., 2015; Paixão et al., 2015; Menezes et al., 2015;
Quintans-Júnior et al., 2016).
Hyptis fruticosa Salzm. ex Benth., Lamiaceae
Lima et al. (2013b) revealed the improvement of the knowl-
edge of the antinociceptive activity of this plant by studying
its potential to treat orofacial pain using formalin, glutamate
and capsaicin pain models, as well as its possible antioxidant
and anti-lipoperoxidative activity. The crude hydroethanol extract
inhibited both nociceptive phases induced by formalin, suggest-
ing the extract has central and peripheral antinociceptive activity,
similarly to morphine, the standard drug used for nociception and
differently from the essential oil of Hyptis fruticosa, which has
antinociceptive peripheral activity (Menezes et al., 2007). Franco
et al. (2011) has assigned the pharmacological effects of this plant
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ue to the variety of volatile compounds found in the leaves such
s, -pinene, -pinene, 1,8-cineole and limonene.
The results of Lima et al. (2013b) showed that the hydroethanol
xtract of the H. fruticosa leaves (CHEE) inhibited the nociception
aused by glutamate with signiﬁcant results for the highest concen-
ration used (200 mg/kg), suggesting that the extract can be active
n inhibiting the painful stimulus induced by this amino acid. CHEE
t 100 and 200 mg/kg was able to reduce the capsaicin nociceptive
ffect, suggesting that vanilloid receptors can be involved in the
HEE action.
cimum basilicum L., Lamiaceae,  and linalool
Venâncio et al. (2011) evaluated earlier the effect of O. basilicum.
amiaceae. The leaf essential oil from O. basilicum (LEO) and its
ajor chemical constituent linalool (LIN) in formalin-, glutamate-
nd capsaicin-induced orofacial nociception in mice and were
nvestigated for whether these substances could also interfere with
he hippocampal neuronal excitability. In the formalin test, there
as a reduction in face rubbing after intraperitoneal injection
f LEO or linalool (LIN). Every dose of linalool tested produced
igniﬁcant antinociceptive action in the ﬁrst and second phase
ompared to control group. LEO manifested its effect only in the
igh dose, while morphine decreased the pain behavior in both
hases. In capsaicin test, LIN or LEO diminished the nociception
videnced by the suppression of the face-rubbing behavior. When
ssessed to glutamate test, LEO and LIN produced marked analge-
ia, but only in higher doses. Batista et al. (2008) demonstrated
hat the antinociceptive effect of LIN may  have a relationship
ith glutamate receptors, namely -amino-3-hydroxy-5-methyl-
-isoxasolepropionic acid (AMPA), NMDA and kainate. These
esults conﬁrmed this hypothesis, since pretreatment with LIN sig-
iﬁcantly protected against the orofacial formalin test. A similar
esult was obtained by acute administration of LEO. It is suggest that
EO and LIN can be considered as non-NMDA glutamate antagonists
AMPA or Kainate blockers). Hence, these behavioral experiments
uggest that most of the analgesic effects of LEO could be attributed
o LIN, its major component. The stimulation of the hylar region
f the dentate gyrus (antidromic stimulation) generated a ﬁeld
otential response in the granular layer, which is characterized
y a major negative component (population spike) followed by a
mall positive phase. Since this response is a consequence of acti-
ation of voltage-dependent sodium channels in the axons of the
ranular cells (Andersen et al., 1971), antagonists of these channels
ere expected to block the response. Similar effects were seen for
EO and LIN, which inhibited the ﬁeld potentials activated by the
ntidromic stimulation of the hylus.
cmella oleracea (L.) R.K. Jansen, Asteraceae
Nomura et al. (2013) examined the antinociceptive effect of
he ethanolic extract obtained from the ﬂowers of Acmella oler-
cea (EEAO) and their results revealed that EEAO (10, 30 and
00 mg/kg) reduced both phases of the formalin-induced orofacial
ociception. Besides, the results decreased the pain in capsaicin-
nd cinnamaldehyde-induced orofacial nociception. Furthermore,
he study also suggested that the analgesic effect of EEAO on the
rofacial nociception mediated by capsaicin and cinammaldehyde
ould be related to TRPV1 and TRPA1 receptor modulation and/or
lockade.
yzygium cumini (L.) Skeels, Myrtaceae
Quintans et al. (2014a) evaluated the antinociceptive effect of
he ethanol extract (EE) from S. cumini leaves on orofacial nocicep-
ion that produced signiﬁcant anti-nociception in the inﬂammatory
hase of the formalin and glutamate test. When glibenclamide
nd l-NOARG were administrated, the antinociception caused by
E was reversed. However, pretreatment with naloxone did note Farmacognosia 27 (2017) 124–134 131
change the antinociceptive action. Muruganandan et al. (2001)
investigated the ethanolic extract of the bark of S. cumini for its
anti-inﬂammatory activity and their results show that this extract
has a powerful anti-inﬂammatory action against distinct phases
of inﬂammation without any side effect on the gastric mucosa.
The anti-inﬂammatory activity of this species was  even studied
by Machado et al. (2013), who investigated the anti-inﬂammatory
and apoptotic activity of the essential oil of S. cumini showing rel-
evant anti-inﬂammatory activity in vivo, possibly due to the high
percentage of -caryophyllene identiﬁed.
Lippia grata Schauer, Verbenaceae
Siqueira-Lima et al. (2014) investigated the possible antinoci-
ceptive activity of -cyclodextrin complex containing Lippia grata
leaf essential oil (-CD/EO) in animal models especially in orof-
acial pain. The results demonstrated that -CD/EO was capable
of reducing the nociceptive face-rubbing behavior in both phases
of the formalin, glutamate and capsaicin induction, possibly due
to the relationship with vanilloid, opioid and cannabinoid recep-
tors. -CD/EO appears to be very effective in activated descending
pain-inhibitory mechanisms without untoward effects already
described for morphine-like drugs (Siqueira-Lima et al., 2014,
2016). Additionally, this study was the ﬁrst to show the chemi-
cal and pharmacological beneﬁts caused by the complexation in
cyclodextrins, which seems to be an advantageous approach to
essential oils and non-polar compounds (Oliveira et al., 2015; Brito
et al., 2015). The cyclodextrins (CD) uses to enhance biological
and chemical characteristics of terpenes and related compounds,
such as essential oils, have been widely explored in the study
of new drugs to treat pain, inﬂammation and cancer because CD
may  promote increased bioavailability and pharmacological efﬁ-
cacy (Siqueira-Lima et al., 2016).
Combretum duarteanum Cambess., Combretaceae
Quintans et al. (2014b) demonstrated that the hexanic extract
and friedelin main be a compound from the Combretum duartenum-
reduced nociception of formalin (in both phases). Glutamate and
capsaicin-induced orofacial nociception tests suggest a possible
interaction with the glutamatergic system and a possible inhibition
of the substance P release or due to a direct block of its neurokinin-
1 receptor (NK-1). These results are supported by previous ﬁndings
of Antonisamy et al. (2011) regarding friedelin, who  attributed the
analgesic proﬁle due to the central and peripheral effects. However,
none of the studies provide molecular evaluations as friedelin can
act by central and peripheral ways.
Anadenanthera colubrina (Vell.) Brenan, Fabaceae
A. colubrina, popularly known as ‘angico-branco’, is native to the
Brazilian Caatinga biome and used by the people to treat respiratory
conditions (asthma, bronchitis, cough and ﬂu), as a skin-healing
agent, analgesic and against inﬂammatory processes (Damascena
et al., 2014) due to its biological properties, Damascena et al.
(2014) sought to assess whether the A. colubrina stem bark aqueous
extract can inhibit orofacial pain induced by chemical agents (for-
malin, capsaicin and glutamate) and investigated the antioxidant
potential. Thus, the A. colubrina stem bark aqueous extract reduced
orofacial pain in all animal models assessed and this effect appears
to be associated with its redox-active radical scavenging activities.
Hypericum perforatum L. Hypericaceae, Valeriana ofﬁcinalis L.,This particular study performed by Nowacki et al. (2015)
assessed the association of hypericum (H. perforatum), valerian
(V. ofﬁcinalis) and kava (P. methysticum) seeking to evaluate
their effects in reducing orofacial pain as well as the possible
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epatic, hematologic and biochemical alterations induced by reg-
lar administration of these extracts. The authors found that the
omposition of these three medicinal plants produced signiﬁcant
nalgesic proﬁle in formalin-induced orofacial pain in rodents, and
lso produced an outstanding hepatoprotective effect.
nimal models of orofacial pain
The importance in the ﬁeld of orofacial pain assessment can
e suggested by the sharp increase in publications over the recent
ecades (Hargreaves, 2011). This fact has also been accompanied by
he increased number of studies using orofacial pain animal mod-
ls, which have sought to better understand the pathophysiology
f orofacial pain and to assess new drugs to treat it (Raboisson and
allel, 2004). There are relatively few behavioral models in labora-
ory animals dedicated to the study of nociception in the trigeminal
egion (Raboisson and Dallel, 2004). Thus, the animal models of
rofacial pain had sought to mimic  symptoms or the disease per se
Khan and Hargreaves, 2010). However, the orofacial pain is mul-
ifactorial and too complex for a single model to incorporate all
he nuances, so there is an increasing number of different types of
nimal models.
As in our survey most studies have sought access to orofacial
ain by chemical stimuli, we made here a brief comment on the
rofacial pain animal models induced by chemical stimuli, such as
ormalin, capsaicin and glutamate (animal models are based on the
nduction of pain by administration of algogen into the vibrissal
ad of rodents).
As described by Hargreaves (2011), this type of animal model
an bring limitations for the analysis of the results because the orof-
cial pain condition is not derived from a unique target tissue, but
rom a variety of sensitive tissues such as the meninges, cornea,
ooth pulp, oral/nasal mucosa and temporomandibular joint. Thus,
he choice of the appropriate method for investigating the phys-
ological or pharmacological event is extremely important in the
tudy design by the researcher.
For the formalin test, probably the best established and most
eliable experimental protocol to assess quickly orofacial pain con-
ition (it is known to be the subcutaneous, s.c.,  injection of dilute
ormalin), which causes indeed tissue injuries and generates behav-
oral as well as electrophysiological responses that last from several
inutes up to more than 1 h (Raboisson and Dallel, 2004). Simi-
arly, as it happens with the administration of formalin into the
odents paw, the injection of formalin in the vibrissa pad (into the
pper lip) produces a biphasic pain stage (Luccarini et al., 2006). It
s a model that evaluates drugs that act centrally or by peripheral
echanisms mediated by local inﬂammation induced by formalin
Raboisson and Dallel, 2004; Hunskaar and Hole, 1987). However, it
s not the best animal model to evaluate painful or analgesic routes.
Recently, two other animal models have been widely used to
ssess drugs with potential analgesic proﬁle to orofacial pain: cap-
aicin and glutamate-induced orofacial pain tests. The application
f capsaicin, the prototypical transient receptor potential vanilloid
 (TRPV1) agonist, evokes neuropeptide release and induces pri-
ary and secondary hyperalgesia (Khan and Hargreaves, 2010). The
dministration of capsaicin into the vibrissa pad of mice induces
igniﬁcant nociceptive behaviors expressed as head ﬂinching and
ubbing of the orofacial tissues during at least 1 h (Holanda-Pinto
t al., 2008). On the other hand, glutamate is one of the most
mportant excitatory neurotransmitters in the production and
anagement of pain (Mogil, 2009). Moreover, glutamate is present
n both central and peripheral terminals of trigeminal and dorsal
oot ganglion neurons (Keast and Stephensen, 2000). According to
uintans-Júnior et al. (2010), the injection of glutamate (volume
f 20 l) into the right upper lip (perinasal area), using a 27-gauge
eedle, caused a persistent nociceptive behavior characterized bye Farmacognosia 27 (2017) 124–134
strong rubbing of the orofacial face and head ﬂinching. Therefore,
drugs that inhibit these behaviors, after administration of capsaicin
or glutamate, are potentially useful as analgesics (Quintans-Júnior
et al., 2010).
Now we  brieﬂy mention the most common animal models to
assess orofacial pain induced by chemical stimuli. More informa-
tion about animal models to study orofacial pain can be assessed in
the excellence reviews published by Raboisson and Dallel (2004),
Mogil (2009), Khan and Hargreaves (2010) and Hargreaves (2011).
Conclusion
This systematic review suggests that the natural compounds
have a potential for the treatment of pain conditions in orofacial
region, hoping to discover new biologically active substances that
may  offer a new possibility for the most appropriate treatment of
orofacial pain, since there is no pharmacological treatments which
may  result in clinical improvement without signiﬁcant side effects
in these pathological conditions. Paradoxically, the studies found
in our survey are very lead-off (basically screenings), which are not
directly related to the possible clinical applicability. Therefore, it
could be believed that pharmacokinetic studies, incorporation into
modern pharmaceutical formulations and biotechnological prod-
uct development seem to be a distant horizon in even the selected
studies. Thus, our opinion is that the evidence found in the studies
showed a possible use of these NP in the management of orofacial
pain conditions. However, new studies are needed to prove their
underlying mechanisms and effects on the molecular level and in
clinical research in a near future.
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